NASDAQ:AMED Amedisys - AMED Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Amedisys, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $93.58 +1.64 (+1.78%) (As of 02/8/2023 12:00 AM ET) Add Compare Share Share Today's Range$91.73▼$94.2050-Day Range$80.12▼$97.0052-Week Range$79.30▼$179.91Volume316,560 shsAverage Volume434,556 shsMarket Capitalization$3.04 billionP/E Ratio25.22Dividend YieldN/APrice Target$128.25 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Amedisys MarketRank™ ForecastAnalyst RatingHold2.47 Rating ScoreUpside/Downside37.0% Upside$128.25 Price TargetShort InterestBearish5.16% of Float Sold ShortDividend StrengthN/ASustainability-0.61Upright™ Environmental ScoreNews Sentiment0.50Based on 6 Articles This WeekInsider TradingN/AProj. Earnings Growth2.07%From $4.83 to $4.93 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.76 out of 5 starsMedical Sector55th out of 1,026 stocksHome Health Care Services Industry4th out of 9 stocks 4.2 Analyst's Opinion Consensus RatingAmedisys has received a consensus rating of Hold. The company's average rating score is 2.47, and is based on 9 buy ratings, 4 hold ratings, and 2 sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $128.25, Amedisys has a forecasted upside of 37.0% from its current price of $93.58.Amount of Analyst CoverageAmedisys has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 2.0 Short Interest Percentage of Shares Shorted5.16% of the float of Amedisys has been sold short.Short Interest Ratio / Days to CoverAmedisys has a short interest ratio ("days to cover") of 3.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous month Previous Next 0.0 Dividend Strength Dividend YieldAmedisys does not currently pay a dividend.Dividend GrowthAmedisys does not have a long track record of dividend growth. Previous Next 5.0 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAmedisys has received a 82.47% net impact score from Upright. Amedisys seems to create the most significant positive value in categories "Jobs", "Meaning & joy", and "Taxes". The positive contribution in the "Meaning & joy" impact category is mostly driven by its "Private hospice care", "Private speech therapy services", and "Private occupational physiotherapy services" products. See details.Environmental SustainabilityThe Environmental Impact score for Amedisys is -0.61. Previous Next 2.5 News and Social Media Coverage News SentimentAmedisys has a news sentiment score of 0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Amedisys this week, compared to 3 articles on an average week.Search Interest7 people have searched for AMED on MarketBeat in the last 30 days. This is an increase of 75% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Amedisys to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Amedisys insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.10% of the stock of Amedisys is held by insiders.Percentage Held by Institutions96.17% of the stock of Amedisys is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Amedisys are expected to grow by 2.07% in the coming year, from $4.83 to $4.93 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Amedisys is 25.22, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 150.62.Price to Earnings Ratio vs. SectorThe P/E ratio of Amedisys is 25.22, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 163.13.Price to Earnings Growth RatioAmedisys has a PEG Ratio of 2.17. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioAmedisys has a P/B Ratio of 3.12. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Amedisys (NASDAQ:AMED) StockAmedisys, Inc. engages in the provision of healthcare services. It operates through the following business segments: Home Health, Hospice, and Personal Care. The Home Health segment delivers services in the homes of individuals who may be recovering from an illness, injury, or surgery. The Hospice segment provides care that is designed to provide comfort and support for those who are facing a terminal illness. The Personal Care segment gives patients assistance with the essential activities of daily living. The company was founded by William F. Borne in 1982 and is headquartered in Baton Rouge, LA.Read More Receive AMED Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Amedisys and its competitors with MarketBeat's FREE daily newsletter. Email Address AMED Stock News HeadlinesFebruary 8, 2023 | finance.yahoo.comAmedisys Honors 39 Employees With Annual Spirit Of Excellence AwardJanuary 30, 2023 | finance.yahoo.comAmedisys Announces Fourth Quarter and Year End Earnings Release and Conference Call DatesFebruary 9, 2023 | Vantage Point (Ad)Predict These Market Breakouts with A.I.We’re looking for breakouts using a simple A.I. tool that you've got to see in our Live Free A.I. Market Training. Breakouts can make or break your trading, so it's critical you know how to predict them 1 - 3 days ahead. They happen at any moment, and they're easier to find with A.I. on your side. January 12, 2023 | finance.yahoo.comBe Wary Of Amedisys (NASDAQ:AMED) And Its Returns On CapitalDecember 28, 2022 | finance.yahoo.comAmedisys to Present at the 41st Annual J.P. Morgan Healthcare ConferenceDecember 23, 2022 | finance.yahoo.comComputerworld Names Amedisys to 2023 List of Best Places to Work in ITDecember 20, 2022 | finance.yahoo.comComputerworld Names Amedisys to 2023 List of Best Places to Work in ITDecember 13, 2022 | finance.yahoo.comAmedisys Completes Home Health Joint Venture with the University of Arkansas for Medical SciencesFebruary 9, 2023 | Vector Vest (Ad)Free Stock Analysis Report: See the Right Way to Analyze StocksGet a full report that tells you what a stock is really worth, how safe the stock is, and if the timing is right to buy the stock. Plus a definitive Buy, Sell, Hold recommendation. December 9, 2022 | finance.yahoo.comDeclining Stock and Solid Fundamentals: Is The Market Wrong About Amedisys, Inc. (NASDAQ:AMED)?December 8, 2022 | finance.yahoo.comAmedisys is Named One of the Most Responsible Companies of 2023 by Statista and NewsweekDecember 2, 2022 | finance.yahoo.comAmedisys to Present at Bank of America Securities Home Care ConferenceNovember 23, 2022 | seekingalpha.comAmedisys: No Change To Thesis, Retain HoldNovember 22, 2022 | finance.yahoo.comAmedisys Names Scott Ginn Acting Chief Operating OfficerNovember 20, 2022 | finance.yahoo.comLast week in management changes and dispatches: Visa, TeslaNovember 18, 2022 | finance.yahoo.comAmedisys Inc. terminates president and CEO, effective immediatelyNovember 18, 2022 | seekingalpha.comAmedisys reaffirms FY22 guidanceNovember 17, 2022 | seekingalpha.comAmedisys CEO Chris Gerard leaves company, effective immediatelyNovember 8, 2022 | finance.yahoo.comAmedisys Third Quarter 2022 Earnings: Misses ExpectationsNovember 3, 2022 | finance.yahoo.comIs There An Opportunity With Amedisys, Inc.'s (NASDAQ:AMED) 30% Undervaluation?November 1, 2022 | finance.yahoo.comAmedisys Statement on CY 2023 Home Health Final RuleOctober 26, 2022 | finance.yahoo.comAmedisys Reports Third Quarter 2022 Financial Results and Updates 2022 GuidanceOctober 25, 2022 | markets.businessinsider.comExpert Ratings for AmedisysOctober 19, 2022 | finance.yahoo.comGlobal Home Healthcare Services Market to Acquire an Impressive Revenue by 2033 and to Grow with a CAGR of ~9% During 2023-2033; Rising Demand for Personal Care for Geriatric Population to Elevate Market Growth – Kenneth Research - Yahoo FinanceOctober 18, 2022 | benzinga.comAmedisys Announces Third Quarter 2022 Earnings Release and Conference Call Date - Amedisys (NASDAQ:AMED) - BenzingaOctober 18, 2022 | finance.yahoo.comAmedisys Announces Third Quarter 2022 Earnings Release and Conference Call DateOctober 11, 2022 | finance.yahoo.comUniversity of Arkansas for Medical Sciences (UAMS) Announces a Partnership with Amedisys and Contessa, Creating a Comprehensive Care at Home Suite of Services - Yahoo FinanceSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive AMED Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Amedisys and its competitors with MarketBeat's FREE daily newsletter. Email Address AMED Company Calendar Last Earnings11/02/2021Today2/08/2023Next Earnings (Confirmed)2/15/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Home health care services Sub-IndustryHealth Care Services SectorMedical Current SymbolNASDAQ:AMED CUSIP02343610 CIK896262 Webwww.amedisys.com Phone(225) 292-2031Fax225-292-8163Employees21,000Year Founded1982Price Target and Rating Average Stock Price Forecast$128.25 High Stock Price Forecast$190.00 Low Stock Price Forecast$85.00 Forecasted Upside/Downside+37.0%Consensus RatingHold Rating Score (0-4)2.47 Research Coverage15 Analysts Profitability EPS (Most Recent Fiscal Year)$3.71 Trailing P/E Ratio25.22 Forward P/E Ratio19.37 P/E Growth2.17Net Income$209.07 million Net Margins5.45% Pretax Margin7.47% Return on Equity16.00% Return on Assets8.48% Debt Debt-to-Equity Ratio0.41 Current Ratio1.06 Quick Ratio1.06 Sales & Book Value Annual Sales$2.21 billion Price / Sales1.37 Cash Flow$8.55 per share Price / Cash Flow10.94 Book Value$29.95 per share Price / Book3.12Miscellaneous Outstanding Shares32,490,000Free Float31,810,000Market Cap$3.04 billion OptionableOptionable Beta1.00 Social Links Key ExecutivesPaul B. K. KusserowChairman & Chief Executive OfficerScott G. GinnEVP, Chief Operating & Financial OfficerMichael P. NorthChief Information OfficerDenise M. BohnertChief Compliance OfficerNick MuscatoChief Strategy OfficerKey CompetitorsLHC GroupNASDAQ:LHCGChemedNYSE:CHEAdaptHealthNASDAQ:AHCOAddus HomeCareNASDAQ:ADUSOption Care HealthNASDAQ:OPCHView All CompetitorsInsiders & InstitutionsSwiss National BankBought 1,100 shares on 2/8/2023Ownership: 0.241%California Public Employees Retirement SystemBought 333 shares on 2/8/2023Ownership: 0.225%Pictet & Cie Europe SASold 2,787 shares on 2/8/2023Ownership: 0.030%Arizona State Retirement SystemBought 302 shares on 2/8/2023Ownership: 0.028%Belpointe Asset Management LLCBought 678 shares on 2/8/2023Ownership: 0.002%View All Insider TransactionsView All Institutional Transactions AMED Stock - Frequently Asked Questions Should I buy or sell Amedisys stock right now? 15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amedisys in the last year. There are currently 2 sell ratings, 4 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" AMED shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in AMED, but not buy additional shares or sell existing shares. View AMED analyst ratings or view top-rated stocks. What is Amedisys' stock price forecast for 2023? 15 brokers have issued 12-month price objectives for Amedisys' stock. Their AMED share price forecasts range from $85.00 to $190.00. On average, they expect the company's stock price to reach $128.25 in the next year. This suggests a possible upside of 37.0% from the stock's current price. View analysts price targets for AMED or view top-rated stocks among Wall Street analysts. How have AMED shares performed in 2023? Amedisys' stock was trading at $83.54 at the start of the year. Since then, AMED shares have increased by 12.0% and is now trading at $93.58. View the best growth stocks for 2023 here. When is Amedisys' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 15th 2023. View our AMED earnings forecast. How can I listen to Amedisys' earnings call? Amedisys will be holding an earnings conference call on Thursday, February 16th at 11:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at 201-612-7415 with passcode "13735891". How were Amedisys' earnings last quarter? Amedisys, Inc. (NASDAQ:AMED) released its quarterly earnings results on Tuesday, November, 2nd. The health services provider reported $1.53 earnings per share for the quarter, beating the consensus estimate of $1.37 by $0.16. The health services provider had revenue of $553.49 million for the quarter, compared to analyst estimates of $568.55 million. Amedisys had a trailing twelve-month return on equity of 16.00% and a net margin of 5.45%. During the same quarter in the previous year, the firm earned $2.24 EPS. How will Amedisys' stock buyback program work? Amedisys announced that its Board of Directors has initiated a stock repurchase plan on Wednesday, August 4th 2021, which permits the company to buyback $100,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization permits the company to repurchase up to 1.2% of its shares through open market purchases. Shares buyback plans are generally an indication that the company's management believes its shares are undervalued. What guidance has Amedisys issued on next quarter's earnings? Amedisys issued an update on its FY 2022 earnings guidance on Sunday, December, 18th. The company provided earnings per share (EPS) guidance of $4.82-$4.93 for the period, compared to the consensus estimate of $4.87. The company issued revenue guidance of $2.22 billion-$2.23 billion, compared to the consensus revenue estimate of $2.23 billion. What is Paul B. Kusserow's approval rating as Amedisys' CEO? 478 employees have rated Amedisys Chief Executive Officer Paul B. Kusserow on Glassdoor.com. Paul B. Kusserow has an approval rating of 79% among the company's employees. 60.0% of employees surveyed would recommend working at Amedisys to a friend. What other stocks do shareholders of Amedisys own? Based on aggregate information from My MarketBeat watchlists, some companies that other Amedisys investors own include NVIDIA (NVDA), Alibaba Group (BABA), Johnson & Johnson (JNJ), Pfizer (PFE), Adobe (ADBE), Intel (INTC), QUALCOMM (QCOM), Broadcom (AVGO), Cisco Systems (CSCO) and Home Depot (HD). What is Amedisys' stock symbol? Amedisys trades on the NASDAQ under the ticker symbol "AMED." Who are Amedisys' major shareholders? Amedisys' stock is owned by a variety of institutional and retail investors. Top institutional investors include Riverbridge Partners LLC (4.70%), Boston Partners (1.00%), Fort Washington Investment Advisors Inc. OH (0.44%), Leeward Investments LLC MA (0.42%), Envestnet Asset Management Inc. (0.36%) and Handelsbanken Fonder AB (0.27%). Insiders that own company stock include Bruce D Perkins, Bruce D Perkins, Christopher Gerard, David L Kemmerly, David L Kemmerly, Denise M Bohnert, Julie D Klapstein, Michael Paul North, Richard A Lechleiter, Scott G Ginn, Sharon Brunecz, Teresa L Kline and Vickie L Capps. View institutional ownership trends. How do I buy shares of Amedisys? Shares of AMED stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Amedisys' stock price today? One share of AMED stock can currently be purchased for approximately $93.58. How much money does Amedisys make? Amedisys (NASDAQ:AMED) has a market capitalization of $3.04 billion and generates $2.21 billion in revenue each year. The health services provider earns $209.07 million in net income (profit) each year or $3.71 on an earnings per share basis. How many employees does Amedisys have? The company employs 21,000 workers across the globe. How can I contact Amedisys? Amedisys' mailing address is 3854 AMERICAN WAY SUITE A, BATON ROUGE LA, 70816. The official website for the company is www.amedisys.com. The health services provider can be reached via phone at (225) 292-2031, via email at ir@amedisys.com, or via fax at 225-292-8163. This page (NASDAQ:AMED) was last updated on 2/9/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.